Survival Outcome of Partial Cystectomy versus Transurethral Bladder Tumor Resection in T1 High-Grade Bladder Cancer Patients: A Propensity Score Matching Study

Zheng Ping,1 Xiangpeng Zhan,2 Tao Chen,2 Yunwei Zheng,2 Ming Jiang,2 Yu Li1,2 and Bin Fu2

1Department of Urology, Shangrao Municipal Hospital, Shangrao, Jiangxi, China
2Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Correspondence should be addressed to Yu Li; 290062469@163.com and Bin Fu; urofbin@163.com

Received 21 July 2022; Revised 21 September 2022; Accepted 10 October 2022; Published 25 October 2022

Academic Editor: Yingming Sun

Copyright © 2022 Zheng Ping et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Partial cystectomy was investigated as a method of bladder preservation with better disease outcomes than transurethral bladder tumor resection in T1 high-grade bladder cancer patients. Method and materials. The national Surveillance, Epidemiology, and End Results database (SEER) (2004–2015) were used to obtain patients diagnosed with T1 high-grade bladder cancer, and finally, 25263 patients were enrolled in our study. The Kaplan–Meier method with the log-rank test was performed to analyze the outcome of overall survival (OS) and cancer-specific survival (CSS) between patients undergoing partial cystectomy (PC), transurethral resection of bladder tumor (TURBT), or radical cystectomy (RC). Moreover, the propensity score matching (PSM) and multivariable Cox proportional hazard model were also utilized in the study. Results. Ultimately, 24635 patients were undergoing TURBT, while 190 and 438 patients were, respectively, assigned to the PC and RC groups. Compared with patients with TURBT, a tendency of a higher proportion of older and male patients was observed in the PC group. When matching with RC patients, patients in the PC group were commonly older and had bigger tumor sizes and single tumors (All $P < 0.05$). After 1 : 1 PSM, 190 patients with TURBT and 160 patients receiving PC were selected. In survival analysis, the patients in the PC group had a higher survival probability of both OS and CSS before and after PSM compared with those in the TURBT group. Meanwhile, no significant differences were observed between the RC and PC groups in OS and CSS analysis. Moreover, multivariable Cox regression showed that PC was a protective factor for overall mortality (ACM) and cancer-specific mortality (CSM) compared with TURBT in T1 high-grade patients (All $P < 0.05$). Conclusion. Patients undergoing partial cystectomy were shown to have a better outcome compared with those with transurethral bladder tumor resection in T1 high-grade bladder cancer patients. Partial cystectomy could be the more worthwhile choice for bladder preservation in T1 high-grade bladder cancer patients.

1. Introduction

Urothelial bladder cancer (UBC) is the 9th most common cancer globally and the most common cancer in the urinary system [1, 2]. 75% of patients diagnosed with UBC are nonmuscle-invasive bladder cancer (NMIBC), and 20% of NMIBC patients are T1 high-grade (T1HG) [3, 4]. T1 high-grade tumors are invasive and have a high probability of disease recurrence and progression to muscle invasion compared with other NMIBC tumors [5]. Now, there are still challenges to the treatment of T1 high-grade tumors, and the main difficulties are choosing between bladder preservation like transurethral resection of the bladder (TURB) with maintenance bacillus Calmette-Guerin (BCG) and aggressive treatment such as radical cystectomy [2, 6]. The bladder preservation approach was considered the ideal treatment and used widely but had a high risk of disease progression and recurrence. For example, a retrospective study that enrolled 1155 patients with T1 high-grade bladder tumors suggested about 25% of cases after the first TURBT
presented residual high-grade disease [7]. Meanwhile, in patients with primary T1HG/G3 treated with maintenance BCG, the residual T1HG/G3 tumor after TURBT would lead to a worse prognosis [8]. In addition, some evidence proved that patients with older age or carcinoma in situ might not be effective in BCG therapy [9, 10]. The difference in the efficacy of BCG for different patients was proved to associate with baseline basophil count, routine systemic inflammatory markers, and systemic combined inflammatory score [11–13]. Radical cystectomy was confirmed as the best chance at cure while it might be overtreatment for some patients with T1HG tumors [5, 6, 14]. These results suggested that the existing treatment for patients with T1HG bladder cancer might still not be satisfactory. Urologists are committed to finding an ideal bladder preservation method with better oncology outcomes given the negative effects of radical cystectomy on patients’ quality of life.

Over the past decade, partial cystectomy as an approach to bladder preservation was explored as a viable alternative to radical cystectomy for some specifically selected MIBC patients, and partial cystectomy offered acceptable outcomes and adequate local control [15, 16]. Partial cystectomy as an alternative to TURBT and RC might gain a balance between disease prognosis and patient’s quality of life for T1HG bladder cancer patients. However, partial cystectomy was not utilized frequently, ranging from 7 to 10% of all cystectomies based on the studies of the National Cancer Database [17]. To our knowledge, no studies focused on PC’s effect in T1HG bladder cancer patients due to insufficient cases. To better understand the treatment effect of PC compared with TURBT and RC in T1HG patients, we searched the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). We enrolled 25264 patients with T1HG tumors who had received surgery of PC, TURBT, or RC. Ultimately, the purpose of this study is to present a relatively good level of evidence for urologists and patients to choose the most suitable and ideal treatment for T1HG bladder cancer patients.

2. Materials and Methods

2.1. Patient Database and Study Population. All patient data were obtained from the Surveillance, Epidemiology, and End Results (SEER), which represented the demographic composition and cancer incidence of the United States population. The conditions for inclusion were as follows: (1) Year of diagnosis: 2004–2015; (2) T stage: T1 high-grade (CS site-Specific Factors 1 code 20); (3) Histology behavior: transitional cell carcinoma (TCC) and papillary transitional cell carcinoma (PTCC); (4) Surgical approach using surgery codes: transurethral bladder tumor resection, partial cystectomy, and radical cystectomy. The following exclusion criteria were also applied: (1) N1, N2, N3, NX (485); (2) M1, MX (270); (3) Grade unknown (1263); (4) Tumor size unknown (7453); (5) Marital status unknown (417).

2.2. Definition of Variables. In our study, patients with T1 high-grade bladder cancer were divided into three groups according to the “RX Summ-Surg Prim Site (1998+)” column in the SEER database, which contained TURBT, PC, and RC. Demographic characteristics of patients included age of diagnosis, sex, race, and marital status. Cancer characteristics incorporated tumor location, tumor grade, histology of the tumor, tumor size, and the number of tumors. Treatment of patients contained surgical approaches, radiation recode, and chemotherapy recode. The race was divided into three categories: white, black, and other styles (American/Indian/Alaska/Native/Asian/Pacific Islander). Marital status was classified into three types: married, SDW (separated, divorced, and widowed), and single. Tumor grade was separated into three groups, including grade I or grade II, III, and IV, to facilitate analysis. Tumor size and the number of tumors were converted to categorical variables as continuous variables. Other variables included: (1) Radiation recode (no/unknown, yes); (2) Histology: transitional cell carcinoma (TCC) and papillary transitional cell carcinoma (PTCC); (3) chemotherapy recode (no/unknown, yes). (4) Tumor site (trigone, dome, lateral, anterior, posterior, bladder neck, ureteric orifice, other sites including overlapping lesion of bladder and bladder, NOS).

2.3. Endpoints. The all-cause mortality (ACM) and cancer-specific mortality (CSM) were the primary endpoints in our study. All-cause mortality matched with any cause of death, and cancer-specific mortality referred to only those who died of bladder cancer. Any patients still were coded as alive if they died after the study cutoff date. The unit of survival time was recorded as a month.

2.4. Statistical Analyses. Propensity score matching (PSM) was performed by SPSS version 22.0 (IBM Corp, Armonk, NY). Baseline characteristics of patients receiving PC were assessed to confirm whether significant differences were compared with patients in other groups. Two-sample t-tests were used for continuous variables while the Chi-square test was for categorical variables to verify heterogeneity between groups. The P < 0.50 was recognized as significant, and all P values of results were two-tailed. The mean ± SD, medians, and interquartile ranges were all presented for continuous variables while frequencies and their proportions were for categorical variables. Survival curves of overall survival (OS) and cancer-specific survival (CSS) were constructed by R studio using the Kaplan–Meier method with the log-rank test. Meanwhile, subgroup analysis of OS and CSS was performed in T1HG patients stratified by age (<70 years and ≥70 years), sex (male and female), histology (transitional cell carcinoma and papillary transitional cell carcinoma), tumor size (<3 cm and ≥3 cm), number of tumors (single and multiple), and grade (Grade III and Grade IV), which could further study the outcomes of T1HG patients. In addition, univariate and multivariate Cox regression analysis was also applied to analyze the prognosis of PC. All results of Cox regression analysis were presented with hazard ratios (HR) and 95% confidence intervals (95% CI). The multivariate Cox regression model adjusted confounding factors which contained age, sex, race, marital status, grade, histology,
3. Results

3.1. Demographics and Clinical Characteristics of the Study Population. Finally, 25263 patients were enrolled in our study. There were 24635 patients receiving TURBT, while 190 and 438 patients were, respectively, assigned to the PC and RC groups. The median follow-up time was 43 months. The number of death cases was 12077, 69, and 214 for those undergoing TURBT, PC, and RC, respectively. We also conducted subgroup analysis stratified by tumor size and number of tumors, and we obtained the results that patients with tumor size bigger than 3 cm or multiple tumors could gain a better prognosis from PC matching with TURBT in terms of OS and CSS (Figure 4). Patients in the PC group all showed longer CSS and OS than those in the TURBT group when stratified by grade and histology, while the statistical difference failed to show in terms of OS in PTCC patients (Figures 5(a)–5(h)). Compared with patients undergoing TURBT with lasers or other energy, patients with PC all presented a better OS and CSS (all \( P < 0.001 \)) (Figure 6). For patients receiving chemotherapy, a better OS and CSS were observed among patients undergoing PC when compared to those with TURBT (Figures 7(a) and 7(b)). However, we failed to obtain statistical differences in OS and CSS in patients without chemotherapy (Figures 7(c) and 7(d)).

3.3. Multivariable Analysis of PC for CSM and ACM before and after PSM. Table 3 demonstrated multivariable Cox proportional hazard models. After adjustments for confounding factors like age, sex, race, marital status, grade, histology, radiotherapy, chemotherapy, tumor size, tumor site, and the number of tumors, the adjusted model all presented that PC was a protective factor for all-cause mortality (ACM) (PC vs. TURBT; \( HR = 0.717, 95\% CI = 0.565–0.908, P = 0.006 \)), while this result failed to gain in terms of cancer-specific mortality (CSM) (PC vs TURBT; \( HR = 0.756, 95\% CI = 0.547–1.044, P = 0.09 \)) before PSM. However, after 1:1 PSM, statistical differences on ACM (PC vs TURBT; \( HR = 0.667, 95\% CI = 0.467–0.952, P = 0.026 \)) and CSM (PC vs TURBT; \( HR = 0.589, 95\% CI = 0.370–0.939, P = 0.026 \)) were both witnessed.

4. Discussion

Our study aimed to investigate an approach in T1HG patients, which could be a better choice than TURBT to preserve the bladder and retained not bad disease prognosis compared with RC. In this study, we confirmed the results that the T1HG patients could gain survival benefit of OS and CSS from PC when matched with TURBT, and most subgroup analyses confirmed the result. Meanwhile, statistical differences were failed to observe between PC and RC on CSS and OS analysis. Moreover, compared to TURBT, multivariate cox regression analysis revealed that PC was a protective factor of ACM and CSM in T1HG patients.

Formerly, partial cystectomy has experienced a resurgence. A growing body of literature has argued that PC might be a viable alternative to RC for select muscle-invasive bladder cancer (MIBC) patients [15, 16, 18]. Considering potential complications of RC like severe blood loss, infections, paralytic ileus, and issues with wound healing and negative effect on long-term life, urologist and patients transferred their focus on PC, which could preserve a complete bladder and function of voiding, avoids urinary diversion, and maintain sexual function [18]. In addition, Umberto Capitanio’s study based on the SEER database got similar results, which showed PC did not enervate the prognosis of OS and CSS in selected patients [19]. A
subsequent retrospective study has also issued a similar conclusion that no differences were seen between PC and RC in metastasis-free or cancer-specific survival [15, 20, 21]. However, some critics of partial cystectomy proclaimed that PC was an incomplete cancer operation following a significant risk of recurrence for MIBC patients and delaying the best treatment time [18, 22]. T1HG tumor was aggressive cancer but in the early stages compared to MIBC tumors. Therefore, partial cystectomy might be worth trying as a method of bladder preservation to replace RC.

As far as we know, few studies were focusing on the impact of TURBT and PC. However, there was research revealed that 50% of patients diagnosed with T1 bladder cancer in the first TURBT displayed residual tumors when a second TURBT was applied, while 10–25% of those patients were confirmed as muscle-invasive bladder cancer.

| Variables                  | No PSM | PSM       |
|----------------------------|--------|-----------|
| Age (year)                 | TURBT  | PC       |
| Mean ± SD                  | 72.9 ± 10.371 | 71.5 ± 9.830 | 0.014*  |
| Median (25th–75th percentile) | 72 (67.5–82) | 72 (67.5–77.5) | 0.016*  |
| Sex                        | 0.041*  | 0.769     |
| Female                     | 51.5 (20.8%) | 28 (14.7%)  | 26 (13.7%) |
| Male                       | 19520 (79.2%) | 162 (85.3%) | 164 (86.3%) |
| Race                       | 0.572   | 0.072     |
| White                      | 21859 (88.7%) | 171 (90.0%) | 162 (85.3%) |
| Black                      | 1448 (5.9%) | 12 (6.3%)  | 10 (5.3%)  |
| Other style                | 1328 (5.4%) | 7 (3.7%)   | 18 (9.5%)  |
| Marital status             | 0.055   | 0.859     |
| Married                    | 15420 (62.6%) | 132 (69.5%) | 135 (71.1%) |
| SDW                        | 6285 (25.5%) | 34 (17.9%) | 30 (15.8%) |
| Single                     | 2930 (11.9%) | 24 (12.6%) | 25 (13.2%) |
| Grade                      | 0.544   | 0.090     |
| Grade I or Grade II        | 517 (2.1%) | 6 (3.2%)   | 2 (1.1%)   |
| Grade III                  | 4926 (20.0%) | 40 (21.1%) | 55 (28.9%) |
| Grade IV                   | 19192 (77.9%) | 144 (75.8%) | 133 (70.0%) |
| Histology                  | 0.119   | 0.047*    |
| TCC                        | 7527 (30.6%) | 68 (35.8%) | 87 (45.8%) |
| PTCC                       | 17108 (69.4%) | 122 (64.2%) | 103 (54.2%) |
| Radiotherapy               | 0.535   | 0.2       |
| No/unknown                 | 24081 (97.8%) | 187 (98.4%) | 183 (96.3%) |
| Yes                        | 554 (2.2%) | 3 (1.6%)   | 7 (3.7%)   |
| Chemotherapy               | 0.127   | 0.618     |
| No/unknown                 | 18389 (74.6%) | 151 (79.5%) | 147 (77.4%) |
| Yes                        | 6246 (25.4%) | 39 (20.5%) | 43 (22.6%) |
| Tumor size                 | 0.267   | <0.001*   |
| ≤3 cm                      | 10919 (44.3%) | 78 (41.1%) | 129 (67.9%) |
| 3–6 cm                     | 9833 (39.9%) | 74 (38.9%) | 54 (28.4%) |
| >6 cm                      | 3883 (15.8%) | 38 (20.0%) | 7 (3.7%)   |
| Tumor site                 | <0.001* | <0.001*   |
| Trigone                    | 1266 (5.1%) | 1 (0.5%)  | 19 (10.0%) |
| Dome                       | 1235 (5.0%) | 29 (15.3%) | 11 (5.8%)  |
| Lateral                    | 4941 (20.1%) | 30 (15.8%) | 35 (18.4%) |
| Anterior                   | 704 (2.9%) | 10 (5.3%)  | 8 (4.2%)   |
| Posterior                  | 2453 (10.0%) | 22 (11.6%) | 23 (12.1%) |
| Bladder neck               | 784 (3.2%) | 2 (1.1%)   | 7 (3.7%)   |
| Ureteric orifice           | 584 (2.4%) | 4 (2.1%)   | 4 (2.1%)   |
| Other sites                | 12668 (51.4%) | 92 (48.4%) | 83 (43.7%) |
| Number of tumors           | 0.880   | <0.001*   |
| Single                     | 14655 (59.5%) | 112 (58.9%) | 74 (38.9%) |
| Multiple                   | 9980 (40.5%) | 78 (41.1%) | 116 (61.1%) |
| Survival time (month)      | 47.498  | 55.121    |
| Mean                       | 55 (37–77) | 55.5 (37–77) | 51.763 |
| Median (25th–75th percentile) | 55 (37–77) | 55.5 (37–77) | 48 (23–81.25) |

PC: partial cystectomy; TURBT: transurethral bladder tumor resection; other race: American/Indian/Alaska/Native/Asian/Pacific Islande; SDW: separated, divorced or widowed; other sites: overlapping lesion of bladder, bladder, NOS; TCC: transitional cell carcinoma, PTCC: papillary transitional cell carcinoma. PSM, propensity score matching. *Statistically significant.
TURBT showed a lousy power of cancer control and accurate pathology report based on the results of these data. Meanwhile, PC removed local tumors, which deleted full-thickness bladder containing lesions, while the alarm of intraoperative bladder perforation still existed in surgery of TURBT. Furthermore, more pathological data obtained like muscle infiltration and lymph node metastasis was the superiority of PC [16, 18, 20]. Simultaneously, BCG shortage was also a challenge for traditional treatment like TURBT following BCG [26]. In summary, PC was a bladder preservation strategy with significant quantity advantages superior to TURBT, and it was an option worth considering for T1HG patients.

In this study, compared with TURBT patients, patients receiving PC tended to be young (71.5 ± 9.830 vs 72.9 ± 10.371, P = 0.014) and had a higher proportion of

| Variables                         | RC (n = 438)  | PC (n = 190) | P value | RC (n = 160)  | PC (n = 190) | P value |
|-----------------------------------|--------------|--------------|---------|---------------|--------------|---------|
| Age (year)                        |              |              |         |               |              |         |
| Mean ± SD                         | 67.9 ± 9.625 | 71.5 ± 9.830 | <0.001* | 69.9 ± 9.408  | 71.5 ± 9.830 | 0.121   |
| Median (25th–75th percentile)     | 67.5 (62–72) | 72 (66–77.5) | <0.001* | 72 (62–77.5)  | 72 (66–77.5) | 0.063   |
| Sex                               |              |              |         |               |              |         |
| Female                            | 64 (14.6%)   | 28 (14.7%)   |         | 25 (15.6%)    | 28 (14.7%)   | 0.968   |
| Male                              | 374 (85.4%)  | 162 (85.3%)  |         | 135 (84.4%)   | 162 (85.3%)  | 0.817   |
| Race                              |              |              |         |               |              |         |
| White                             | 387 (88.4%)  | 171 (90.0%)  |         | 144 (90.0%)   | 171 (90.0%)  | 0.496   |
| Black                             | 25 (5.7%)    | 12 (6.3%)    |         | 6 (3.8%)      | 12 (6.3%)    | 0.14    |
| Other style                       | 26 (5.9%)    | 7 (3.7%)     |         | 10 (6.3%)     | 7 (3.7%)     | 0.318   |
| Marital status                    |              |              |         |               |              |         |
| Married                           | 301 (68.7%)  | 132 (69.5%)  |         | 117 (73.1%)   | 132 (69.5%)  | 0.826   |
| SDW                               | 74 (16.9%)   | 34 (17.9%)   |         | 30 (18.8%)    | 34 (17.9%)   | 0.063   |
| Single                            | 63 (14.4%)   | 24 (12.6%)   |         | 13 (8.1%)     | 24 (12.6%)   | 0.121   |
| Grade                             |              |              |         |               |              |         |
| Grade I or Grade II               | 9 (2.1%)     | 6 (3.2%)     |         | 1 (0.6%)      | 6 (3.2%)     | 0.703   |
| Grade III                         | 95 (21.7%)   | 40 (21.1%)   |         | 38 (23.8%)    | 40 (21.1%)   | 0.042*  |
| Grade IV                          | 334 (76.3%)  | 144 (75.8%)  |         | 121 (75.6%)   | 144 (75.8%)  | 0.13    |
| Histology                         |              |              |         |               |              |         |
| TCC                               | 185 (42.2%)  | 68 (35.8%)   |         | 53 (33.1%)    | 68 (35.8%)   | 0.653   |
| PTCC                              | 253 (57.8%)  | 122 (64.2%)  |         | 107 (66.9%)   | 122 (64.2%)  | 0.0403  |
| Radiotherapy                      |              |              |         |               |              |         |
| No/unknown                        | 433 (98.9%)  | 187 (98.4%)  |         | 159 (99.4%)   | 187 (98.4%)  | 0.842   |
| Yes                               | 5 (1.1%)     | 3 (1.6%)     |         | 1 (0.6%)      | 3 (1.6%)     | 0.038   |
| Chemotherapy                      |              |              |         |               |              |         |
| No/unknown                        | 345 (78.8%)  | 151 (79.5%)  |         | 126 (78.8)    | 151 (79.5%)  | 0.457   |
| Yes                               | 93 (21.2%)   | 39 (20.5%)   |         | 34 (21.3%)    | 39 (20.5%)   | 0.042*  |
| Tumor size                        |              |              |         |               |              |         |
| ≤3 cm                             | 323 (73.7%)  | 78 (41.1%)   | <0.001* | 87 (54.4%)    | 78 (41.1%)   | 0.41    |
| 3–6 cm                            | 86 (19.6%)   | 74 (38.9%)   |         | 46 (28.7%)    | 74 (38.9%)   | 0.047*  |
| >6 cm                             | 29 (6.6%)    | 38 (20.0%)   |         | 27 (16.9%)    | 38 (20.0%)   | 0.041*  |
| Tumor site                        |              |              |         |               |              |         |
| Trigone                           | 14 (3.2%)    | 1 (0.5%)     | <0.001* | 8 (5.0%)      | 1 (0.5%)     | 0.003   |
| Dome                              | 17 (3.9%)    | 29 (15%)     |         | 15 (9.4%)     | 29 (15.3%)   | 0.045   |
| Lateral                           | 49 (11.2%)   | 30 (15.8%)   |         | 34 (21.3%)    | 30 (15.8%)   | 0.043   |
| Anterior                          | 11 (2.5%)    | 10 (5.3%)    |         | 7 (4.4%)      | 10 (5.3%)    | 0.041   |
| Posterior                         | 29 (6.6%)    | 22 (11.6%)   |         | 12 (7.5%)     | 22 (11.6%)   | 0.041   |
| Bladder neck                      | 11 (2.5%)    | 2 (1.1%)     |         | 4 (2.5%)      | 2 (1.1%)     | 0.041   |
| Ureteric orifice                  | 6 (1.4%)     | 4 (2.1%)     |         | 1 (0.6%)      | 4 (2.1%)     | 0.041   |
| Other sites                       | 301 (68.7%)  | 92 (48.4%)   |         | 79 (49.4%)    | 92 (48.4%)   | 0.041   |
| Number of tumor                   |              |              |         |               |              |         |
| Single                            | 183 (41.8%)  | 112 (58.9%)  | <0.001* | 88 (55.0%)    | 112 (58.9%)  | 0.457   |
| Multiple                          | 255 (58.2%)  | 78 (41.1%)   |         | 72 (45.0%)    | 78 (41.1%)   | 0.041   |

Survival time (months)

|                           | RC (n = 160) | PC (n = 190) | P value | RC (n = 160) | PC (n = 190) | P value |
|---------------------------|--------------|--------------|---------|--------------|--------------|---------|
| Mean                      | 60.021       | 55.121       | 0.40    | 59.106       | 55.121       | 0.196   |
| Median (25th–75th percentile) | 62 (39–86)   | 55.5 (37–77) | 0.038*  | 60.5 (39–82.75) | 55.5 (37–77) | 0.157   |

PC: partial cystectomy; RC: radical cystectomy; other race: American/Indian/Alaska/native/Asian/Pacific Islande; SDW: separated, divorced or widowed; other sites: overlapping lesion of bladder, bladder, NOS; TCC: transitional cell carcinoma, PTCC: papillary transitional cell carcinoma. PSM, propensity score matching. *Statistically significant.

[22–25].
male (85.3% vs 79.2%, \( P = 0.041 \)). When matched with the RC group, the PC group appeared older (71.5 ± 9.830 vs 67.9 ± 9.625, \( P < 0.001 \)) and were more likely to have a single tumor (58.9% vs 41.8%, \( P < 0.001 \)). This result confirmed with criteria of adopting PC developed by MD Anderson [16, 20]. However, a higher proportion of bigger tumors size was observed in the PC group, which might be the cause of insufficient sample size.

Survival analysis in propensity score-matched subgroups was performed to precisely compare the efficacy between PC.
and TURBT. In the subgroup of age \( > 70 \), male, tumour size \( < 3 \) cm, multiple, grade III, and IV, histology of transitional cell carcinoma and papillary transitional cell carcinoma, T1HG patients with PC all showed better survival outcomes of OS and CSS than those with TURBT. Nevertheless, it failed to gain significant differences in OS and CSS analysis in the subgroup of age \( < 70 \), female, tumour size \( \geq 3 \) cm, and single. More similar studies were needed to confirm these results.

Up to our knowledge, it is the first study to propose the idea of performing PC as a method of bladder preservation in T1HG patients. Utilization of propensity matching score method to perform potential confounding factors and

---

**Figure 2**: Survival curve with the Kaplan–Meier method between RC and PC patients: (a) before PSM for OS; (b) before PSM for CSS (c) after PSM for OS (d) after PSM for CSS.
Figure 3: Continued.
reduce selective bias was also the advantage of this study. Detailed subgroup analysis also made the results more convincing. However, there were still some limitations in our study. Firstly, unavoidable selection bias still existed in this retrospective study even PSM was applied. Then, the number of patients receiving PC is still not enough to go further study, and it might be the reason for insignificant differences in subgroup analysis and multivariate cox
**Figure 4: Continued.**
regression analysis. In addition, the SEER database lacked some important disease outcomes such as tumor recurrence and progression, and they are also essential evaluation indexes for surgery. Meanwhile, more detail information of partial cystectomy like surgical approach was failed to obtain due to limitation of SEER database. Ultimately, statistical differences in demographics and clinical characteristics of the study population remained after PSM. The patients of the RC and PC group failed to match 1:1 in performing PSM owing to insufficient patients with RC (160 for RC vs 190 for
Figure 5: Continued.
PC after PSM). Consequently, a prospective study with a larger sample size and a more rigorous design is needed to verify these results.

Finally, some problems of PC were needed to attach importance to. For some special patients with carcinoma in situ (CIS), tricky tumor location including ureteral orifice or bladder neck and multiple tumors, we need to carefully consider the effect of partial cystectomy for these patients [16, 18, 20]. In addition, the COVID-19 pandemic posed unprecedented challenges to our health system and delays in

---

**Figure 5:** Survival curve with the Kaplan–Meier method between TURBT and PC patients after PSM subgroup analysis by grade and histology: (a–d) for OS; (e–h) for CSS.
Figure 6: Survival curve with the Kaplan–Meier method between TURBT and PC patients after PSM subgroup analysis: (a and b) (TURBT with other energy); (c and d) (TURBT with lasers).
**Figure 7:** Figure 6 survival curve with the Kaplan–Meier method between TURBT and PC patients after PSM subgroup analysis by whether receiving chemotherapy: (a and c) for OS; (b and d) for CSS.
Table 3: Univariate and multivariable Cox proportional hazard model for PC.

| Outcomes | PC HR (95% CI), (TURBT ref.) | P value |
|----------|------------------------------|---------|
| Overall mortality | | |
| Nonadjusted | 0.650 (0.513–0.824) | P < 0.001* |
| Adjusted | 0.717 (0.565–0.908) | P = 0.006* |
| PSM nonadjusted | 0.562 (0.417–0.758) | P < 0.001* |
| PSM adjusted | 0.667 (0.467–0.952) | P = 0.026* |
| Cancer-specific mortality | | |
| Nonadjusted | 0.664 (0.481–0.917) | 0.013* |
| Adjusted | 0.756 (0.547–1.044) | P = 0.09 |
| PSM nonadjusted | 0.474 (0.319–0.705) | P < 0.001* |
| PSM adjusted | 0.589 (0.370–0.939) | P = 0.026* |

Nonadjusted: univariate Cox regression analysis for PC. All model adjusted for: age, sex, race, marital status, grade, histology, radiotherapy, chemotherapy, tumor size, tumor site, number of tumors. PC: partial cystectomy; PSM: propensity score matching. *Statistically significant.

5. Conclusions

Partial cystectomy was proven to have a better outcome of overall survival and cancer-specific survival when compared with transurethral bladder tumor resection in T1 high-grade patients. In addition, no difference in overall survival and cancer-specific survival was observed between patients undergoing partial cystectomy and those undergoing radical cystectomy. Partial cystectomy could be a worthwhile choice for bladder preservation in T1 high-grade bladder cancer patients.

Data Availability

The data in this article come from the SEER database. This data can be found here: https://seer.cancer.gov/data/.

Ethical Approval

A preprint has previously been published [28]. This study was supported by the National Natural Science Foundation of P.R. China (Grant Nos. 81560419, 81960512, and 81760457), Jiangxi Provincial "Double Thousand Plan" Fund Project (Grant No. jxsx201920127), Key Project of Natural Science Foundation of Jiangxi Province (20212ACB206013), and Youth Project of Natural Science Foundation of Jiangxi Province (20212BAB216037).

Acknowledgments

A preprint has previously been published [28]. This study was supported by the National Natural Science Foundation of P.R. China (Grant Nos. 81560419, 81960512, and 81760457), Jiangxi Provincial "Double Thousand Plan" Fund Project (Grant No. jxsx201920127), Key Project of Natural Science Foundation of Jiangxi Province (20212ACB206013), and Youth Project of Natural Science Foundation of Jiangxi Province (20212BAB216037).

References

[1] Y. P. Song, A. McWilliam, P. J. Hoskin, and A. Choudhury, "Organ preservation in bladder cancer: an opportunity for truly personalized treatment," Nature Reviews Urology, vol. 16, no. 9, pp. 511–522, 2019.
[2] Z. Klaassen, A. M. Kamat, W. Kassouf et al., "Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations," European Urology, vol. 74, no. 5, pp. 597–608, 2018.
[3] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and J. A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[4] Z. Kirkali, T. Chan, M. Manoharan et al., "Bladder cancer: epidemiology, staging and grading, and diagnosis," Urology, vol. 66, no. 6, pp. 4–34, 2005.
[5] A. Lopez-Beltran and L. Cheng, "Stage T1 bladder cancer: diagnostic criteria and pitfalls," Pathology, vol. 53, no. 1, pp. 67–85, 2021.
[6] E. De Berardinis, G. M. Busetto, G. Antonini, R. Giovannone, and V. Gentile, "T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy," International Urology and Nephrology, vol. 43, no. 4, pp. 1047–1057, 2011.
[7] M. Ferro, G. Di Lorenzo, C. Buonerba et al., "Predictors of residual T1 high grade on Re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-gradegrade 3 bladder cancer," Journal of Cancer, vol. 9, no. 22, pp. 4250–4254, 2018.
[8] M. Ferro, M. D. Vartolomei, F. Cantiello et al., "High-grade T1 on Re-transurethral resection after initial high-grade T1 confers worse oncological outcomes: results of a multi-institutional study," Urologia Internationalis, vol. 101, no. 1, pp. 7–15, 2018.
[9] M. Ferro, S. Chiujdea, G. Musi et al., "Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: multi-institutional cohort analysis," Clinical Genito-Urinary Cancer, vol. 20, no. 2, pp. e166–e172, 2022.
[10] M. Ferro, M. Marchioni, G. Lucarelli et al., "Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study," Minerva Urology and Nephrology, vol. 73, no. 6, pp. 796–802, 2021.
[11] M. Ferro, G. Di Lorenzo, M. D. Vartolomei et al., "Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder.
tumor,” World Journal of Urology, vol. 38, no. 1, pp. 143–150, 2020.
[12] M. Ferro, M. Di Mauro, S. Cimino et al., “Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer,” Translational Andrology and Urology, vol. 10, no. 2, pp. 626–635, 2021.
[13] F. Cantelli, G. I. Russo, M. D. Vartolomei et al., “Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer,” European Urology Oncology, vol. 1, no. 5, pp. 403–410, 2018.
[14] M. Babjuk, M. Burger, E. M. Comperat et al., “European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update,” European Urology, vol. 76, no. 5, pp. 639–657, 2019.
[15] J. M. Holzbeierlein, E. Lopez-Corona, B. H. Bochner et al., “Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection,” The Journal of Urology, vol. 172, no. 3, pp. 878–881, 2004.
[16] W. Kassouf, D. Swanson, A. M. Kamat et al., “Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson cancer center experience,” The Journal of Urology, vol. 175, no. 6, pp. 2058–2062, 2006.
[17] A. S. Kibel, “Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007,” Year Book of Urology, vol. 2011, pp. 218–220, 2011.
[18] J. Knoedler and I. Frank, “Organ-sparing surgery in urology: partial cystectomy,” Current Opinion in Urology, vol. 25, no. 2, pp. 111–115, 2015.
[19] U. Capitanio, H. Isbarn, S. F. Shariat et al., “Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis,” Urology, vol. 74, no. 4, pp. 858–864, 2009.
[20] T. C. Peak and A. Hemal, “Partial cystectomy for muscle invasive bladder cancer: a review of the literature,” Translational Andrology and Urology, vol. 9, no. 6, pp. 2938–2945, 2020.
[21] J. J. Knoedler, S. A. Boorjian, S. P. Kim et al., “Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis,” The Journal of Urology, vol. 188, no. 4, pp. 1115–1119, 2012.
[22] R. Klän, V. Loy, and H. Huland, “Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder,” The Journal of Urology, vol. 146, no. 2 Part 1, pp. 316–318, 1991.
[23] H. Kitamura and Y. Kakehi, “Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?” Japanese Journal of Clinical Oncology, vol. 45, no. 4, pp. 315–322, 2015.
[24] A. Brauers, R. Buettner, and G. Jakse, “Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?” The Journal of Urology, vol. 165, no. 3, pp. 808–810, 2001.
[25] L. Schips, H. Augustin, R. E. Zigeuner et al., “Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?” Urology, vol. 59, no. 2, pp. 220–223, 2002.
[26] R. Veeratterapillay, R. Heer, M. I. Johnson, R. Persad, and C. Bach, “High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage,” Current Urology Reports, vol. 17, no. 9, p. 68, 2016.
[27] M. Ferro, F. Del Giudice, G. Carrieta et al., “The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: a retrospective multi-institutional cohort analysis,” Cancers, vol. 13, no. 21, p. 5276, 2021.
[28] X. Zhan and B. Fu, “Partial cystectomy could Be a better option of bladder preservation in T1 high-grade bladder cancer patients: a propensity score matching study,” 2021. PREPRINT (Version 1) available at Research Square.